Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.

• Klíčová slova
• CD19, chimeric antigen receptor, chronic lymphocytic leukemia, immunotherapy,
• MeSH
• antigeny CD19 imunologie   MeSH
• B-lymfocyty imunologie   MeSH
• chimerické antigenní receptory imunologie   MeSH
• chronická lymfatická leukemie imunologie   terapie   MeSH
• imunoterapie adoptivní metody   MeSH
• indukce remise MeSH
• lidé MeSH
• T-lymfocyty imunologie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• antigeny CD19 MeSH
• CD19 molecule, human MeSH Prohlížeč
• chimerické antigenní receptory MeSH